Now, in the case of BRAF-mutated tumor, they can receive vemurafenib (anti-BRAF target drug) and have ∼50% chance of response [12], or, irrespectively of BRAF mutation, ipilimumab (immune checkpoint inhibitor) with ∼20% chance of long-term (>5 years) disease control [13]. The gene discussed is BRAF; the disease is neoplasm.